Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets
出版年份 2022 全文链接
标题
Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 16, Pages 8875
出版商
MDPI AG
发表日期
2022-08-10
DOI
10.3390/ijms23168875
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- siRNA drug Leqvio (inclisiran) to lower cholesterol
- (2022) Julia M. Migliorati et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Combinational silencing of components involved in JAK/STAT signaling pathway
- (2022) Emira Bousoik et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma
- (2021) Priya Kumthekar et al. Science Translational Medicine
- Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity.
- (2021) Antonio Sacco et al. BLOOD
- Teprasiran, A Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study
- (2021) Matthias Thielmann et al. CIRCULATION
- Conditional Antisense Oligonucleotides Triggered by miRNA
- (2021) Jiahui Zhang et al. ACS Chemical Biology
- STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications
- (2021) Isidora Tošić et al. NEOPLASIA
- Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
- (2020) Timothy Miller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clusterin: Always protecting. Synthesis, function and potential issues
- (2020) Carmen Rodríguez-Rivera et al. BIOMEDICINE & PHARMACOTHERAPY
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia – spotlight on volanesorsen
- (2019) Dimitrios Milonas et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines
- (2019) Emily Linnane et al. NUCLEIC ACIDS RESEARCH
- Chromosomal Density of Cancer Up-Regulated Genes, Aberrant Enhancer Activity and Cancer Fitness Genes Are Associated with Transcriptional Cis-Effects of Broad Copy Number Gains in Colorectal Cancer
- (2019) Daniele Filippo Condorelli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment?
- (2019) Choi et al. Cancers
- Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
- (2019) Jinkuk Kim et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
- (2018) Jonathan E. Rosenberg et al. BRITISH JOURNAL OF CANCER
- A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
- (2018) Laeeq Malik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
- (2018) Richard S. Finkel et al. NEUROMUSCULAR DISORDERS
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
- (2018) David Adams et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
- (2018) Merrill D. Benson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligonucleotide Drugs for Transthyretin Amyloidosis
- (2018) Joel N. Buxbaum NEW ENGLAND JOURNAL OF MEDICINE
- Application of 2′-O-(2-N-Methylcarbamoylethyl) Nucleotides in RNase H-Dependent Antisense Oligonucleotides
- (2018) Yoshiaki Masaki et al. Nucleic Acid Therapeutics
- Positive Caricature Transcriptomic Effects Associated with Broad Genomic Aberrations in Colorectal Cancer
- (2018) Daniele F. Condorelli et al. Scientific Reports
- Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives
- (2018) Julie E. Bauman et al. CANCER
- STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
- (2018) Dayson Moreira et al. CLINICAL CANCER RESEARCH
- P53 in kidney injury and repair: Mechanism and therapeutic potentials
- (2018) Chengyuan Tang et al. PHARMACOLOGY & THERAPEUTICS
- Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
- (2018) Isabella Faraoni et al. Cancers
- Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
- (2017) Kim N Chi et al. LANCET ONCOLOGY
- Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
- (2017) Tomasz M Beer et al. LANCET ONCOLOGY
- Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
- (2017) Michael J. Wagner et al. MOLECULAR CANCER THERAPEUTICS
- FDA-Approved Oligonucleotide Therapies in 2017
- (2017) Cy A. Stein et al. MOLECULAR THERAPY
- Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides
- (2017) Naoki Iwamoto et al. NATURE BIOTECHNOLOGY
- Cellular uptake and trafficking of antisense oligonucleotides
- (2017) Stanley T Crooke et al. NATURE BIOTECHNOLOGY
- A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
- (2017) Andrew H. Ko et al. ONCOLOGIST
- Adult-onset spinal muscular atrophy: An update
- (2017) R. Juntas Morales et al. REVUE NEUROLOGIQUE
- Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
- (2017) Sarah J. Ross et al. Science Translational Medicine
- RNA splicing process analysis for identifying antisense oligonucleotide inhibitors with padlock probe-based isothermal amplification
- (2017) Xiaojun Ren et al. Chemical Science
- Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma
- (2017) Antonio Miguel et al. OncoTargets and Therapy
- Chromosomal instability analysis and regional tumor heterogeneity in colon cancer
- (2017) Vincenza Barresi et al. Cancer Genetics
- Eteplirsen in the treatment of Duchenne muscular dystrophy
- (2017) Kenji Rowel Lim et al. Drug Design Development and Therapy
- Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
- (2016) Seiichi Odate et al. CLINICAL CANCER RESEARCH
- The biological effects and clinical implications of BRCA mutations: where do we go from here?
- (2016) Dominique Stoppa-Lyonnet EUROPEAN JOURNAL OF HUMAN GENETICS
- Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer
- (2016) A.G. Duffy et al. INTERNATIONAL JOURNAL OF CANCER
- Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway
- (2016) Xiaoning Feng et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab
- (2016) David I. Rosenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells
- (2016) Peixin Dong et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Synthesis of Phosphorodiamidate Morpholino Oligonucleotides and Their Chimeras Using Phosphoramidite Chemistry
- (2016) Sibasish Paul et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2
- (2016) Mateusz Rytelewski et al. Oncotarget
- Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development
- (2016) Tatiana M. Tilli et al. Oncotarget
- Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
- (2015) Y. Yamamoto et al. CLINICAL CANCER RESEARCH
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments
- (2015) Yoshiki Sekijima JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
- (2015) Talia Golan et al. Oncotarget
- Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys
- (2015) Sebastien A. Burel et al. Nucleic Acid Therapeutics
- Androgen receptor: structure, role in prostate cancer and drug discovery
- (2014) MH Eileen Tan et al. ACTA PHARMACOLOGICA SINICA
- Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention
- (2014) Samantha Kaufhold et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Delivery of Antisense Peptide Nucleic Acids to Cells by Conjugation with Small Arginine-Rich Cell-Penetrating Peptide (R/W)9
- (2014) Céline Cordier et al. PLoS One
- Antisense Oligonucleotide Therapies
- (2014) Kendall S. Frazier TOXICOLOGIC PATHOLOGY
- Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases
- (2014) Kavitha Siva et al. Nucleic Acid Therapeutics
- Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
- (2014) Pedro M. D. Moreno et al. Frontiers in Chemistry
- KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas
- (2013) Alyssa M Krasinskas et al. MODERN PATHOLOGY
- Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
- (2013) Nicolai Juul Birkbak et al. PLoS One
- Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival
- (2012) D. J. Hartman et al. INTERNATIONAL JOURNAL OF CANCER
- Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA
- (2012) Peter Järver et al. Molecular Therapy-Nucleic Acids
- Delayed Graft Function in the Kidney Transplant
- (2011) A. Siedlecki et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Regulatory T cells and Foxp3
- (2011) Alexander Y. Rudensky IMMUNOLOGICAL REVIEWS
- KRAS mutant allele-specific imbalance in lung adenocarcinoma
- (2011) Simion I Chiosea et al. MODERN PATHOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Ocular neuroprotection by siRNA targeting caspase-2
- (2011) Z Ahmed et al. Cell Death & Disease
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer
- (2009) Biljana Culjkovic et al. Journal of Oncology
- Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
- (2008) Richard D. Sowery et al. BJU INTERNATIONAL
- The role of hypoxia-inducible factors in tumorigenesis
- (2008) E B Rankin et al. CELL DEATH AND DIFFERENTIATION
- Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer
- (2008) Kim N Chi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started